Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) Stock Information | RedChip

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)


$9.5100
-0.0100 ( -0.11% ) 0.4K

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Market Data


Open


$9.5100

Previous close


$9.5200

Volume


0.4K

Market cap


$650.95M

Day range


$9.3350 - $9.3350

52 week range


$6.0650 - $19.7100

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 58 Nov 07, 2024
8-k 8K-related 14 Nov 07, 2024
8-k 8K-related 20 Aug 19, 2024
8-k 8K-related 14 Aug 08, 2024
10-q Quarterly Reports 57 Aug 08, 2024
8-k 8K-related 13 Jul 18, 2024
4 Insider transactions 1 Jul 17, 2024
4 Insider transactions 1 Jul 17, 2024
4 Insider transactions 1 Jul 17, 2024
10-q/a Quarterly Reports 59 Jun 14, 2024

Latest News